Electronic glasses company eSight has released the results of an independent study that demonstrates its effectiveness as a clinical device for people living with visual impairment.

The device is designed to enable people living with vision loss to independently carry out everyday activities.

The study, *The effect of a head-mounted low vision device on visual function*, which has been published in *Optometry and Vision Science*, details the results of 51 study participants across six low vision research and rehabilitation institutions in the US and Canada.

President and CEO of eSight, Dr Brian Mech, said the results substantiate the real-life improvements in functional vision provided by the company’s wearable technology.

“This is an affirmation of over 12 years and tens of millions of dollars in research and development, and a milestone for both our company and the visually impaired community that we are dedicated to empowering,” Dr Mech explained.

The study tested 51 people with low vision requirements prior to and after being fitted with eSight’s electronic glasses. They were also tested after three months of at-home use of the device.

eSight found that patients experienced ‘significant improvement’ in objective visual function measures, activities of daily living and patient-reported quality of life outcomes.
Study highlights clinical effectiveness of eSight

Study author, Dr Walter Wittich, from the Université de Montréal, added: “Self-reported outcomes suggest that visual abilities, such as reading, are greatly improved when wearing the device.”

Additionally, patients did not experience a decline in mobility performance from wearing the assistive technology device.

Should’ve worked for a global brand?
Don’t be a should’ve

Your Comments

You must be logged in to join the discussion. Log in

Comments (0)

More Equipment and Suppliers Articles

Training from Haag-Streit

UV protection with every lens

Creating consistency

Aiming to educate
View all equipment and suppliers

2 Woodbridge Street
London
EC1R 0DG
Study highlights clinical effectiveness of eSight